Home › Health › Children hit hardest as scientists race to understand...
Health

Children hit hardest as scientists race to understand rare Ebola outbreak

Children hit hardest as scientists race to understand rare Ebola outbreak
Key Points

Children hit hardest as scientists race to understand rare Ebola outbreak More than 1,200 children under five have contracted the rare Bundibugyo strain in the Democratic Republic of Congo, with scientists investigating why it is proving so deadly - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today. Join todayAlready a member?

Children hit hardest as scientists race to understand rare Ebola outbreak More than 1,200 children under five have contracted the rare Bundibugyo strain in the Democratic Republic of Congo, with scientists investigating why it is proving so deadly - Bookmark - CommentsGo to comments Become an Independent member to bookmark this article Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Membership today. Join todayAlready a member? Log in Children are being disproportionately affected by a deadly Ebola outbreak in the Democratic Republic of Congo, with around seven in 10 infected under-fives dying as scientists race to understand a rare strain of the virus. More than 1,200 children under the age of five have contracted the Bundibugyo strain in the outbreak, and 844 have died, according to the latest figures from the Congolese health ministry and the World Health Organization (WHO). The fatality rate among young children is higher than the roughly 50 per cent recorded among adults, raising questions about why the virus is proving particularly dangerous for the youngest patients. More than six months into the outbreak, scientists and medical teams are gathering evidence about the rare strain in the hope of improving diagnosis, treatment and efforts to stop its spread. There have been more than 11,000 cases and over 5,500 deaths so far. The virus has spread at twice the pace of the 2014-2016 West African Ebola outbreak, the largest on record. Unlike the more common Zaire strain, there are currently no licensed vaccines or treatments specifically for Bundibugyo. Why children are being hit so hard One challenge is that the symptoms can differ from what doctors and communities might expect from Ebola. While the disease can cause fever, vomiting, diarrhoea and, in severe cases, internal and external bleeding, bleeding appears to be much less common in this outbreak. Yap Boum, Africa Centres for Disease Control and Prevention's deputy Ebola incident manager, said bleeding was occurring in around 5 to 10 per cent of confirmed cases. This can make the virus harder to recognise, with symptoms potentially mistaken for more common illnesses such as malaria. The WHO's Ebola incident manager, Catherine Smallwood, said young children were presenting particular diagnostic challenges because gastrointestinal symptoms were more common than fever. This could be contributing to delays in diagnosis and treatment, she said. The outbreak is also unfolding in an area of eastern Congo already facing a humanitarian crisis, making it harder for medical teams to identify cases and provide care. Around 70 per cent of patients are still dying in their communities rather than in healthcare facilities, according to the report. Scientists believe the virus may have been spreading for months before the outbreak was officially declared in May. Scientists search for answers Researchers are still trying to establish how often people experience milder symptoms, what the longer-term effects of infection might be and whether existing medical interventions can help. Genomic sequencing has found that Bundibugyo is distinct from more common Ebola viruses, but there is currently no evidence that it is rapidly changing or becoming more transmissible. Prompt access to medical care significantly improves a patient's chances of survival, experts say. Standard measures such as isolating infected patients have also helped bring transmission under control in some of the outbreak's early hotspots. The biggest unanswered question is whether vaccines and treatments developed for other Ebola strains can work against Bundibugyo. A trial of Merck's Ervebo vaccine, which was developed to protect against the Zaire strain, is assessing whether it could offer some protection against the rarer virus. Vaccines designed specifically for Bundibugyo are also expected to enter trials, while medical teams in Congo are testing antiviral drugs and treatments from Gilead Sciences and Mapp Biopharmaceutical. Around 700 survivors have enrolled in a study and support programmes, according to the WHO. Daniel Bausch, a member of the WHO's Ebola emergency committee, cautioned that comparisons between outbreaks were difficult because of differences in the circumstances and available data. But Boum said evidence that any vaccine or treatment could offer protection would represent a significant breakthrough. “When we started, we said there are no vaccines, no treatments,” he said. “If we start proving we have some efficacy... it becomes a game changer.” Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
Bundibugyo (ORG) the Democratic Republic of Congo (LOCATION) Independent (ORG) Log in Children (ORG) Congolese (ORG) the World Health Organization (ORG) West African (ORG) Zaire (LOCATION) Yap Boum (PERSON) WHO (ORG) Catherine Smallwood (PERSON) Congo (LOCATION)
Originally published by The Independent World Read original →